AP2212A - Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases. - Google Patents

Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.

Info

Publication number
AP2212A
AP2212A AP2006003675A AP2006003675A AP2212A AP 2212 A AP2212 A AP 2212A AP 2006003675 A AP2006003675 A AP 2006003675A AP 2006003675 A AP2006003675 A AP 2006003675A AP 2212 A AP2212 A AP 2212A
Authority
AP
ARIPO
Prior art keywords
monophosphonamidates
bisphosphonamidates
phosphonates
treatment
viral diseases
Prior art date
Application number
AP2006003675A
Other languages
English (en)
Other versions
AP2006003675A0 (en
Inventor
Xiaqin Cheng
Gary P Cook
Manoj C Desai
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2006003675A0 publication Critical patent/AP2006003675A0/xx
Application granted granted Critical
Publication of AP2212A publication Critical patent/AP2212A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/664Amides of phosphorus acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AP2006003675A 2003-12-30 2004-12-29 Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases. AP2212A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53374503P 2003-12-30 2003-12-30
US59098704P 2004-07-26 2004-07-26
US60659504P 2004-09-01 2004-09-01
PCT/US2004/043969 WO2005066189A1 (en) 2003-12-30 2004-12-29 Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases

Publications (2)

Publication Number Publication Date
AP2006003675A0 AP2006003675A0 (en) 2006-08-31
AP2212A true AP2212A (en) 2011-03-01

Family

ID=34753695

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003675A AP2212A (en) 2003-12-30 2004-12-29 Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.

Country Status (28)

Country Link
US (5) US7553825B2 (hr)
EP (2) EP2204374B1 (hr)
JP (2) JP4949852B2 (hr)
KR (2) KR20120080240A (hr)
CN (2) CN1950383B (hr)
AP (1) AP2212A (hr)
AT (1) ATE478082T1 (hr)
AU (2) AU2004312546B2 (hr)
BR (1) BRPI0418251C1 (hr)
CA (1) CA2550222C (hr)
CY (2) CY1111050T1 (hr)
DE (1) DE602004028763D1 (hr)
DK (2) DK2204374T3 (hr)
EA (1) EA011304B1 (hr)
ES (2) ES2350983T3 (hr)
HK (2) HK1097276A1 (hr)
HR (3) HRP20060254A2 (hr)
IL (1) IL176407A (hr)
IS (1) IS2994B (hr)
NO (2) NO338001B1 (hr)
NZ (1) NZ548771A (hr)
PL (3) PL1716162T3 (hr)
PT (2) PT1716162E (hr)
RS (2) RS51476B (hr)
SG (1) SG149075A1 (hr)
SI (2) SI1716162T1 (hr)
WO (1) WO2005066189A1 (hr)
ZA (1) ZA200606049B (hr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
CA2485702C (en) * 2002-05-13 2011-07-19 Metabasis Therapeutics, Inc. Novel phosphonic acid based prodrugs of pmea and its analogues
US7193081B2 (en) 2002-05-13 2007-03-20 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of PMEA and PMPA
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
KR101108439B1 (ko) 2002-10-25 2012-01-31 포믹스 리미티드 화장료 및 약제용 거품제
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
ES2350983T3 (es) 2003-12-30 2011-01-28 Gilead Sciences, Inc. Fosfonatos, monofosfonamidatos, bisfosfonamidatos para el tratamiento de enfermedades víricas.
US7582758B2 (en) * 2004-06-08 2009-09-01 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
WO2007002912A2 (en) * 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
WO2007002808A1 (en) * 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof
PT2020996E (pt) * 2006-05-16 2012-02-20 Gilead Sciences Inc Método e composições para tratar neoplasias malignas hematológicas
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
TWI399377B (zh) * 2006-07-07 2013-06-21 Gilead Sciences Inc 類鐸受體7之調節劑
CA2659095C (en) 2006-07-14 2015-04-28 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102309984B (zh) * 2011-07-22 2013-05-01 华东师范大学 一种磷酸酰胺类双功能催化剂及其合成方法
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
EA201892769A3 (ru) 2013-03-15 2019-08-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Сложные диэфиры ациклических нуклеозидфосфонатов
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
WO2015161785A1 (zh) * 2014-04-21 2015-10-29 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
AU2015317972B2 (en) 2014-09-15 2019-10-17 The Regents Of The University Of California Nucleotide analogs
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN107820499B (zh) * 2015-04-28 2022-11-11 鲁汶大学研究与开发部 抗病毒化合物、其制备工艺、以及其用于治疗病毒感染的用途
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
WO2017106069A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
CN107849075A (zh) * 2016-01-19 2018-03-27 四川海思科制药有限公司 一种核苷类似物的磷酰胺酯前药及其应用
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN108137630A (zh) * 2016-09-23 2018-06-08 鲁汶天主教大学 氟化无环核苷膦酸酯的前药
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
BR112019013017A2 (pt) 2016-12-22 2020-01-14 Idenix Pharmaceuticals Llc compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos
EP3558322B1 (en) 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
CN108276444A (zh) * 2017-01-06 2018-07-13 米文君 一类新的化合物及其用途
US20190374557A1 (en) * 2017-02-28 2019-12-12 Alexandre Vasilievich Ivachtchenko Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
GB2590198B (en) 2017-12-07 2022-02-23 Univ Emory N4-hydroxycytidine derivatives and anti-viral uses related thereto
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528490C2 (de) * 1975-06-26 1983-04-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung saurer Protease
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU3540101A (en) 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
PL213214B1 (pl) * 2000-07-21 2013-01-31 Gilead Sciences Diastereoizomerycznie wzbogacone proleki fosfonianowych analogów nukleotydowych oraz kompozycje zawierajace takie zwiazki
DE10236294A1 (de) * 2001-08-17 2003-02-27 Alstom Switzerland Ltd Gasversorgungskontrolleinrichtung einer Gasspeicherkraftanlage
CN1168449C (zh) * 2002-12-23 2004-09-29 梁有国 抗人乳头瘤病毒感染的药物
ES2350983T3 (es) 2003-12-30 2011-01-28 Gilead Sciences, Inc. Fosfonatos, monofosfonamidatos, bisfosfonamidatos para el tratamiento de enfermedades víricas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN ET AL.: "In vivo anti-papilomavirus activity of nucleoside analogues inciudinh cidofovir on CRPV-induced rabbit papillomas" ANTIVIRAL RESEARCH, vol. 48, 2000, pages 131-142 *
KEITH ET AL.: "Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 47, no. 7, July 2003 (2003-07), pages 2193-2198 *
SNOECK ET AL.: "Antivaccinia Activities of Acyclic Nucleoside Phosphonate Derivatives in Epithelial Cells and Organotypic Cultures" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 11, November 2002 (2002-11), pages 3356-3361 *

Also Published As

Publication number Publication date
EP2204374B1 (en) 2012-06-13
HRP20100626T1 (hr) 2011-03-31
KR20120080240A (ko) 2012-07-16
ZA200606049B (en) 2008-01-08
EA011304B1 (ru) 2009-02-27
ES2389602T3 (es) 2012-10-29
PL212403B1 (pl) 2012-09-28
JP2011137029A (ja) 2011-07-14
CY1113103T1 (el) 2016-04-13
WO2005066189A1 (en) 2005-07-21
AU2004312546A1 (en) 2005-07-21
NO20150615L (no) 2005-07-01
US7553825B2 (en) 2009-06-30
BRPI0418251B1 (pt) 2019-09-24
EP1716162B1 (en) 2010-08-18
IL176407A0 (en) 2006-10-05
CN101816664B (zh) 2012-04-18
ATE478082T1 (de) 2010-09-15
BRPI0418251C1 (pt) 2021-05-25
US20060046981A1 (en) 2006-03-02
EP2204374A1 (en) 2010-07-07
SI1716162T1 (sl) 2010-12-31
SG149075A1 (en) 2009-01-29
US20090291922A1 (en) 2009-11-26
AU2011200141A1 (en) 2011-02-03
DE602004028763D1 (de) 2010-09-30
BRPI0418251B8 (pt) 2019-10-08
PT1716162E (pt) 2010-11-24
PT2204374E (pt) 2012-09-17
IS8516A (is) 2006-06-21
US20090149400A1 (en) 2009-06-11
HRP20120699T1 (hr) 2012-09-30
US20060030545A1 (en) 2006-02-09
NO338040B1 (no) 2016-07-25
CY1111050T1 (el) 2015-06-11
HRP20060254A2 (en) 2006-10-31
DK1716162T3 (da) 2011-01-10
HK1097276A1 (en) 2007-06-22
RS52433B (en) 2013-02-28
ES2350983T3 (es) 2011-01-28
IL176407A (en) 2012-12-31
CN1950383B (zh) 2010-06-09
HK1146061A1 (en) 2011-05-13
KR20060129360A (ko) 2006-12-15
NZ548771A (en) 2010-05-28
SI2204374T1 (sl) 2012-09-28
AU2004312546B2 (en) 2010-10-14
US8268802B2 (en) 2012-09-18
NO20063479L (no) 2006-10-02
CN101816664A (zh) 2010-09-01
AP2006003675A0 (en) 2006-08-31
JP4949852B2 (ja) 2012-06-13
KR101214257B1 (ko) 2012-12-21
US8088754B2 (en) 2012-01-03
JP2007517065A (ja) 2007-06-28
EA200601263A1 (ru) 2006-12-29
IS2994B (is) 2018-03-15
EP1716162A1 (en) 2006-11-02
BRPI0418251A (pt) 2007-04-17
CA2550222A1 (en) 2005-07-21
RS51476B (en) 2011-04-30
PL380828A1 (pl) 2007-03-19
PL2204374T3 (pl) 2012-11-30
AU2011200141B2 (en) 2012-02-16
US20050222090A1 (en) 2005-10-06
DK2204374T3 (da) 2012-09-10
NO338001B1 (no) 2016-07-18
CA2550222C (en) 2013-05-28
CN1950383A (zh) 2007-04-18
PL1716162T3 (pl) 2011-02-28

Similar Documents

Publication Publication Date Title
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
EG25300A (en) Process for the manufacture of 1,2-dichloroethane.
EG25281A (en) Process for the manufacture of 1,2-dichloroethane.
EP1594512A4 (en) COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
AP2005003232A0 (en) Combination therapy for hyperproliferative diseases.
HK1078087A1 (en) Process for the preparation of (s,s)-cis-2-benzhydryl-3- benzylaminoquinuclidine
EP1545558A4 (en) 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
IL177490A0 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AP2006003514A0 (en) Piperazine derivatives for the treatment of HIV infections.
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
HK1064261A1 (en) Method for the treatment of tobacco.
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
MXPA03004454A (es) Derivados de imidazolona para el tratamiento de enfermedades virales.
SI1663244T1 (sl) Pteridinski derivati za zdravljenje bolezni, povezanih s TNF-alfa
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
AU2003284212A8 (en) Process for the preparation of (s,s)-cis-2-phenyl-3-aminopiperidine
ITUD20030080A1 (it) Procedimento per effettuare transazioni commerciali.
GB0315877D0 (en) Compounds for the treatment of disease